Iodobenzene → 8-Morpholino-3-phenylimidazo[1,2-b]pyridazine-2-carbaldehyde
Reaction equation
[O:1]1[CH2:6][CH2:5][N:4]([C:7]2[C:8]3[N:9]([CH:13]=[C:14]([CH:16]=[O:17])[N:15]=3)[N:10]=[CH:11][CH:12]=2)[CH2:3][CH2:2]1.I[C:19]1[CH:24]=[CH:23][CH:22]=[CH:21][CH:20]=1>>[O:1]1[CH2:2][CH2:3][N:4]([C:7]2[C:8]3[N:9]([C:13]([C:19]4[CH:24]=[CH:23][CH:22]=[CH:21][CH:20]=4)=[C:14]([CH:16]=[O:17])[N:15]=3)[N:10]=[CH:11][CH:12]=2)[CH2:5][CH2:6]1Participants
3
Procedure
Compound 5e (300 mg, 1.3 mmol) was coupled with iodobenzene (0.21 mL, 1.9 mmol) according to the procedures described in Example 20, Step A to afford compound 74a. 1H NMR (400 MHz, CDCl3) δ (ppm): 10.11 (s, 1H), 8.09 (d, J=5.6 Hz, 1H), 7.73 (d, J=8.1 Hz, 2H), 7.44-7.63 (m, 3H), 6.13 (d, J=5.6 Hz, 1H), 4.04-4.16 (m, 4H), 3.80-4.02 (m, 4H).
Sources & evidence
- ORD record
- ord-51b8c0359afe4b29aa57510addc1fe6b
- Source dataset
- uspto-grants-2015_11
- Patent number
- US09193736B2
Reaction notes
Loading…